Purchase this article with an account.
E. Romo-Garcia, G. Alvarez-Rivera, M. Gordon, V. Kon-Jara, M. Martinez-Castellanos, D. Moreno-Paramo, J. Guerrero-Naranjo, H. Quiroz-Mercado; Is Intravitreal Bevacizumab an Efective Treatment for Coats Disease?. Invest. Ophthalmol. Vis. Sci. 2007;48(13):94.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the short-term safety of intravitreal bevacizumab and its effects on visual acuity and anatomical changes in patientes with Coats disease.
Four eyes of 4 patients with Coats disease were included in a pilot study. Patients were treated at baseline with a 2.5 mg / 0.1 ml intravitreous bevacizumab injection; full opthalmologic evaluations were performed at baseline and at 1, 4, 8, 12 and 24 weeks. The evaluations included biomicroscopy, visual acuity mesurement, along with optical coherence tomography imaging and fluorescein angiography.
Average patient age was 17years old. There were no ocular or sytemic adverse events identified at the six month follow-up. Serial examinations documented an involutional response with a reduction of the subretinal fluid, exudates and macular thickness; visual acuity improved in all cases, but the improvement lasted for 3 months.
Intravitreal injection of Bevacizumab was well tolerated, and resulted in a transient improvement in visual acuity, optical coherence tomography and angiographic outcome. Bevacizumab therapy could be considered in patients with Coats disease, but further studies exploring combined treatment with laser or cryotherapy should be undertaken.
This PDF is available to Subscribers Only